A B S T R A C T Factor VII can be activated, to a molecule giving shorter clotting times with tissue factor, by incubating plasma with kaolin or by clotting plasma. The mechanisms of activation differ. With kaolin, activated Factor XII (XIIa) was the apparent principal activator. Thus, Factor VII was not activated in Factor XII-deficient plasma, was partially activated in prekallikrein and high-molecular weight kininogen (HMW kininogen)-deficient plasmas, but was activated in other deficient plasmas. After clotting, activated Factor IX (IXa) was the apparent principal activator. Thus, Factor VII was not activated in Factor XII-, HMW kininogen-, XI-, and IX-deficient plasmas, but was activated in Factor VIII-, X-, and V-deficient plasmas. In further studies, purified small-fragment Factor XIIa (,8-XIIa), kallikrein, and Factor IXa were added to partially purified Factor VII and to plasma.
INTRODUCTION
Factor VII activity, as measured in one-stage Factor VII clotting assays (1), increases several fold when blood is exposed to a surface such as glass or kaolin (1), or when blood is allowed to clot (2) . Factor VII activity also increases when plasma from women taking oral contraceptives is stored at 4°C (3) . The increased Factor VII activity is thought to stem from an accelerated initial rate of reaction between Factor VII, tissue factor, and calcium ions, which leads to an increased rate of accumulation of Factor Xa and, subsequently, thrombin in the clotting mixture of one-stage Factor VII assays (4) . In purified bovine preparations, the increased Factor VII activity has been shown to be associated with conversion of a native single-chain Factor VII molecule into a two-chain molecule (5, 6) , and, therefore, may be viewed as an activation of Factor VII.
We report here the results of a systematic evaluation of the mechanism of activation of Factor VII after surface contact and after clotting. Data were obtained from whole plasma systems and from mixtures containing purified clotting factors. The findings establish that the enzymes involved in the activation of Factor VII after surface contact differ from the enzymes involved in the activation of Factor VII after clotting and clarify the roles of activated Factor XII, kallikrein, and Factor IXa in each circumstance.
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Reagents
Tissue factor wvas a saline extract of human brain tissue (7) centrifuged twice at 12,000 g to remove large particulate material. It clotted recalcified normal plasma in 17 s. A reference standard plasma assumed to contain 1 U/ml activity of all clotting factors was prepared by pooling plasma from 12 healthy males and was stored at -20°C. Severe hereditary clotting factor-deficient plasmas were obtained from patients seen in this laboratory, from a commercial source (George King, BioMedical, Overland Park, Kans.) or through the courtesy of Dr. C. Hougie, University of California, San Diego, and of Dr. C. Kasper and Dr. S. Schiffman, University of Southern California, Los Angeles.
All chemicals used were of the best grade available from commercial sources. Tris-buffered saline (TBS)l was a solution containing Tris 0.05 M and NaCl 0.15 M, pH 7.5 TBS containing bovine serum albumin (TBS-BSA) was made by adding BSA (Sigma Chemical Co., St. Louis, 'Mo.) to TBS in a final concentration of 1 mg/ml.
Assays of Factor VII
A clotting assay for Factor VII was carried out by incubating 25 ,ul of hereditary Factor VII-deficient plasma, 50 ul of tissue factor, and 25 ,ul of adsorbed bovine plasma in a 12 x 75-mm glass tube for 3 min at 37°C. Then, 25 ,ul of test materials and 50 ,ul of 35 mM calcium chloride were added and the clotting time noted. A 1:10 dilution in TBS was used for plasma or serum samples with an expected normal or low Factor VII level. A 1:100 to 1:300 dilution in TBS was used for plasma or serum samples with an expected high Factor VII activity. When partially purified Factor VII was assayed, it was diluted in TBS-BSA. Clotting times were converted to units per milliliter from a dilution curve prepared with 1:10-1:80 dilutions in TBS of the reference standard plasma.
A coupled amidolytic assay for Factor VII, developed in this laboratory, is described in detail elsewhere (4) . It is carried out in two steps. In the first, the test material containing Fac- tor VII is incubated at 37°C with tissue factor, calcium ions, and purified Factor X. The generation of Factor Xa is stopped at 3 min by adding Na2 EDTA and placing the mixture in ice. In the second step the Factor Xa activity is measured by adding a subsample of the incubation mixture to an aliquot of the specific chromogenic substrate (S-2222) (Bz-Ile-GlyGlu-Arg-p-nitroanilide) and by determining the initial rate of its cleavage in a spectrophotometer. In contrast to the clotting assay, the coupled amidolytic assay measures total Factor VII level independent of the activity state of Factor VII (4). Therefore, an increase in Factor VII activity in the clotting assay but not in the coupled amidolytic assay is taken as evidence for activation of Factor VII.
Purified human clotting factors
Factor IX. Factor IX was purified by a modification of a published method (8) and as described in detail elsewhere (9) . ' Abbreviations used in this paper: BSA, bovine serum albumin; HMW kininogen, high-molecular weight kininogen; SDS sodium dodecyl sulfate; TBS, Tris-buffered saline.
It involved BaSO4 absorption, batch chromatography on DE-11 Whatman cellulose (Whatman Inc., Clifton, N. J.), preparatory polyacrylamide gel electrophoresis, heparin-agarose chromatography, and concentration on a small DEAE cellulose column. Preparations contained 5-20 U/ml of Factor IX as measured in a clotting assay (10) and by electroimmunoassay (11) with a 207 clotting U/mg protein sp act (9) . Before storage, preparations yielded comparable values by the two assay techniques. After storage at -20°C in 0.05 NI Tris-HCl, 0.375 Ml NaCl, pH 7.5, purified preparations gave higher values by electroimmunoassay than in the clotting assay. For example, the stored preparation used for one series of experiments had a final concentration of 1.68 U/ml by electroimmunoassay and 0.85 U/ml in the clotting assay. When stored preparations were incubated for 20 min with Factor XIa and calcium ions, the amount of Factor IXa generated, as measured by a coupled amidolytic assay (12) was that expected for the level of Factor IX as measured by electroimmunoassay.
The lower values obtained in the one-stage clotting assay could stem from aggregation of purified Factor IX on storage,2 with resultant slowing of its initial rate of activation by Factor XIa. Because in the experiments described here Factor IX was incubated over hours with Factor XIa or kallikrein, we have expressed Factor IX concentration in units per milliliter as measured by electroimmunoassay. Labeling of purified Factor IX with 1251 was carried out by the chloramine T method (13) and as described in detail elsewhere (9) . The incubation time with chloramine T was 2.5 min at room temperature.
Factor IXa. Factor IX,, was prepared, as described (12) , by incubating purified Factor IX with Factor XIa and CaCl2, and separating the Factor IX,, from the Factor XI,, with DEAEcellulose chromatography. Factor IXa concentration was measured by a coupled amidolytic technique (12) and by electroimmunoassay (11) . Higher values were obtained in the electroimmunoassay than in the coupled amidolytic assay, e.g., in one preparation 4.04 U/ml by electroimmunoassay and 0.88 U/ml by the coupled amidolytic assay. Because Factor XIa. Factor XI. was prepared as described (12) .
Factor VII. Factor VII was partially purified by a modification of a described method (12) . The preparation contained 14.8 U/ml Factor VII in the clotting assay and 16 U/ml in the coupled amidolytic assay described above. The preparation also contained 0.5 U/ml prothrombin activity as determined in a clotting assay (18 (20) .
Anti-Factor X antiserum. An antiserum against Factor X was prepared with purified Factor X in a goat (12) . The immunoglobulin fraction from the goat serum was separated by 40% (NH4)2 SO4 precipitation and DEAE-cellulose chromatography (21 Antiprothrombin antiserum. An antiserum against prothrombin was prepared in a goat, with purified prothrombin kindly provided by Dr. Bruce and Dr. Barbara Furie of the Tufts Medical School, Boston, Mass. The goat immunoglobulin fraction was separated from serum by DEAESephadex column chromatography, 50% ammonium sulfate precipitation, and concanavalin A affinity column chromatography. The gamma globulin fraction gave a single precipitation line of identity on double immunodiffusion against purified prothrombin and normal plasma. Mixing equal parts of this preparation with the partially purified Factor VII preparation completely neutralized the prothrombin activity of the latter as measured in a one-stage assay for prothrombin (18) . The gamma globulin fraction also inhibited the ability of purified human thrombin to clot fibrinogen in normal plasma.
Antiprekallikrein antiserum. An antiprekallikrein antiserum was prepared with purified prekallikrein in a goat (23) . The gamma globulin fraction containing the antiprekallikrein antibody was separated from the goat serum by a procedure that involved kaolin absorption, incubation at 56°C for 30 min, DEAE-cellulose batch chromatography, 50% ammonium sulfate precipitation, and dialysis into 0.01 M Tris, 0.4 M NaCl pH 7.5. 1 part of the gamma globulin fraction neutralized 0.65 parts of a purified kallikrein solution containing 1 U/ml as measured in an amidolytic assay (17) . The gamma globulin fraction gave a single line of identity with purified prekallikrein and normnal plasma on double immunodiffusion.
Antiplasminogen antiserum. An antiserum against plasminogen was prepared with purified plasminogen in a goat (24) . One part of the gamma globulin fraction neutralized >95% of the plasminogen activity present in 2 parts of normal plasma as measured on fibrin plates after the addition of streptokinase.
Control normal goat gamma globulin. The gamma globulin fraction from the serum of a normal goat was prepared by the technique used to isolate the gamma globulin fraction of the antiprothrombin antibody.
Measurement of cleavage of 125I-Factor IX and 1251-Factor XII Activation of Factor IX and of Factor XII is associated with limited proteolysis of the native single polypeptide chain zymogens to yield products giving characteristic patterns of the polypeptide fragments on reduced SDS-polyacrylamide gel electrophoresis (9, 15) . When either purified 125I-Factor IX or '25I-Factor XII is added to a test mixture, activation of that particular clotting factor can be evaluated from the radioactivity profile of a SDS-polyacrylamide gel electrophoresis gel by relating the integrated radioactivity of the cleavage products to the sum of integrated radioactivities of the native uncleaved factor and the cleavage products.
The cleavage of Factor IX was measured after the clotting of citrated plasma in 12 x 75-mm-glass tubes and incubation ofthe clots for 2.5 h at 37°C. 15 gl of2-U/ml purified 1251-Factor IX were added to 200-,ul plasma samples before the addition of 100 A1 of 35 mM CaCl2. 2.5 h after clotting the clots were removed and 25 gl of0.3 M Na2 EDTA was added to the serum to prevent calcium-dependent aggregation of Factor IX (9). 4.5 ,ul of serum was then transferred to 1.5 ml snap cap polypropylene centrifuge tubes to which 50 gl 3% SDS and 10 ,ul mercaptoethanol were added. The mixtures were then boiled for 5 min and subjected to polyacrylamide gel electrophoresis in the presence of SDS on 10% gels (6 mm x 8 cm) (19) . After electrophoresis, the radioactivity profile was obtained by counting gel slices (1.3 mm) in a Searle gamma spectrometer (Searle Diagnostics, Inc., Des Plaines, Ill.) and plotting on paper radioactivity against the slice number. The precent cleavage of 125I-Factor IX was determined as described above.
In experiments on contact activation of plasma by kaolin, 1 ,ul of a 60-ug/ml preparation of 125I-Factor XII was added to 200 ,lI of plasma in snap cap polypropylene tubes. 20 ,l of 20-mg/ml kaolin was added and the mixture incubated for 4.5 h at 4°C. A 4.5-,l sample of the kaolin-plasma suspension was removed and added to 50 Al of 3% SDS and 10 ,l of mercaptoethanol in a polypropylene tube. The mixture was then boiled for 5 min and centrifuged for 5 min at 8,000g. The supernate was removed and treated as described above. Under these conditions >90% ofthe 125I-Factor XII is removed from the kaolin.
RESULTS
Activation of Factor VII in plasmas incubated with kaolin. Factor VII activity in plasma from healthy subjects and from patients with different hereditary clotting factor deficiencies was measured in the clotting assay and in the coupled amidolytic assay before and after incubation ofthe plasma samples with kaolin. The incubation was carried out by adding 20 ,1. of a 20-mg/ ml kaolin suspension to 200 ,ul of citrated plasma and allowing the mixture to stand, with occasional shaking, at 4°C for 4.5 h. The kaolin was then removed by centrifugation. As shown in Table I , exposure to kaolin increased the Factor VII activity of normal plasma as measured in the clotting assay but not as measured in the coupled amidolytic assay. This evidence of Factor VII activation was found in all of the deficient plasmas except Factor XII-deficient plasma. However, in highmolecular weight (HMW) kininogen-deficient plasma and in prekallikrein-deficient plasma the extent of activation of Factor VII appeared to be less than in normal plasma.
Purified '25I-Factor XII was added to plasma from three additional healthy subjects. Incubation of these plasma samples with kaolin at 40C resulted in a 55-63% cleavage of the 125I-Factor XII, and was associated with a 4.5-to 7-fold increase in Factor VII activity in the clotting assay.
Incubation ofnormal plasma with kaolin for 4.5 h was also carried out at 37°C. A four-to fivefold increase in the clotting activity of Factor VII was observed.
Activation of Factor VII induced by clotting of plasma. Factor VII activity was measured in the clotting assay and the coupled amidolytic assay before and after recalcification of plasmas and incubation of the clots. 200 ,ul of normal plasma or a clotting factor- and incubated under our experimental conditions. A representative experiment is shown in Fig. 1 . In experiments with plasma from six subjects 40-46% of the Factor IX was cleaved after 2.5 h in the serum. This was associated with a 4.5-to 5-fold increase in Factor VII activity measured in the clotting assay. ,8-XIIa would be generated by the activation of 16% of the Factor XII in normal plasma.
However, at higher concentrations, /3-XIIa activated partially purified Factor VII. Thus, at a final concentration of 8.8 ,ug/ml Of ,8-XIIa, which would be equivalent to 90% cleavage of Factor XII in plasma, an -twofold activation of partially purified Factor VII was observed. A concentration of 35 ,ug/ml, which corresponds to four times the maximum concentration of f3-XIIa attainable in plasma, was required to produce the degree of activation observed when normal plasma was incubated with kaolin under similar conditions (Table I) .
Purified ,8-XIIa was much more effective in activating
Factor VII in plasma than in activating partially purified Factor VII. When ,3-XIIa at a final concentration of 1.7 ,ug/ml was incubated (plastic tube, 40C, 4 h) with either normal plasma or with Factor VII-deficient plasma that was reconstituted with partially purified Factor VII a 4-to 4.5-fold increase in Factor VII activity was found (Fig. 3) . However, Factor VII was not activated when the same experiment was carried out with HMW kininogen-deficient plasma or prekallikrein-deficient plasma. A delayed and partial activation was seen when Factor XII-deficient plasma was used. When Factor XI-deficient plasma or Factor IXdeficient plasma was used the extent of activation approached that found with normal plasma, with a resultant -threefold activation of Factor VII. FIGURE 3 Effect of purified ,3-XIIa on the Factor VII activity of normal plasma and different hereditary deficient plasmas (dp). In all experiments the final concentration of I-XIIa was 1.7 ,ug/ml. Initial Factor VII levels in these plasmas varied from 0.47 to 1.25 U/ml. The line marked IXdp is the mean of results obtained with plasma from four severe hemophilia B patients and the lines marked XIdP, XIIdp, HMWK(HMW kininogen)dp, and PK(prekallikrein)dp represent the data for plasma from single patients with each of these hereditary deficiencies.
Effect of purified plasnma kallikreini upont factor VII activity. Factor VII activity failed to increase when purified kallikrein at a final concentration of either 1.0 or 5.7 U/ml was incubated at 40C for 4 h with partially purified Factor VII. However, Factor VII activity increased fourfold when purified kallikrein at a final concentration of 1.0 U/ml was incubated in a plastic tube at 40C for 4 h with a mixture of partially purified Factor VII and Factor VII-deficient plasma. Factor VII activity increased similarly when kallikrein was incubated with normal plasma, hereditary Factor XIIdeficient plasma, or hereditary Factor IX-deficient plasma.
Because kallikrein reportedly activates plasminogen (24) and plasmin activates Factor VII (25), Factor VII activity was also measured after adding kallikrein to Factor XII-deficient plasma that had been incubated with an antiserum to plasminogen. One part of Factor XII-deficient plasma was incubated for 10 min at 37°C with 0.7 parts of either an antiplasminogen antiserum or a control normal goat gamma globulin fraction. Then kallikrein was added at a final concentration of 2.3 U/ml and the mixtures were incubated for 4 h at 4°C. In both incubation mixtures Factor VII activity increased by 3.8-fold.
Because kallikrein also activates Factor IX (9), we next carried out experiments in which purified kallikrein (final concentration 1.9 U/ml) and purified Factor IX (final concentration 2.5 U/ml) were incubated at 40C with partially purified Factor VII (final con- clots were removed and the serum assayed for Factor VII activity in the clotting assay. The differences between the Factor VII activity in the original plasma and in the serum were as follows: with normal plasma, a sixfold increase in activity; with Factor VIII-deficient plasma, a sevenfold increase in activity; with Factor X-deficient plasma, an eightfold increase in activity. Increased Factor VII activity was also found when lower final concentrations of Factor IXa were used. For example, when the final concentration of Factor IXa in the mixture was 0.4 U/ml by the amidolytic assay and 1 U/ml by the electroimmunoassay, the following increases were observed: with normal plasma, a threefold increase; with Factor VIII-deficient plasma, a fivefold increase; and with Factor X-deficient plasma, a 4.5-fold increase.
To determine whether Factor IXa directly activates Factor VII in plasma or whether it might also lead indirectly to Factor VII activation through a plasma intermediate, an experiment was designed employing antibodies against Factor IX. 10 ,tl of a Factor IXa preparation containing 3.9 U/ml by electroimmunoassay and 0.85 U/ml by coupled amidolytic assay, was incubated with 20 ,l of Factor VII-deficient plasma for 3.5 h at 4°C. Then, either 10 Al of anti-Factor IX antiserum (an amount that inhibited all detectable Factor IX activity) or 10 ,ul of adsorbed normal rabbit serum was added and the mixture was incubated for 10 min at 37°C. At this point, 10 Al of a 4.0 U/ml partially purified Factor VII was added to the mixtures, which were further incubated at 4°C to allow generation of increased Factor VII activity. Subsamples were removed at various times for measurement of Factor VII clotting activity. Factor VII activity steadily rose in the control incubation mixture containing nonimmune serum and showed a fourfold increase in Factor VII activity after 4 h of incubation. Factor VII activity failed to rise in the incubation mixture containing the Factor IX antiserum. Thus, it appeared that Factor IXa did not activate Factor VII in plasma through the generation of an intermediate.
Further evidence for a direct activation of Factor VII by Factor IXa was obtained from experiments in which increasing concentrations of purified native Factor IX were incubated at 37°C for 20 min with purified Factor XIa and calcium ions to generate Factor IXa. Then, partially purified Factor VII was added to the incubation mixtures, which were incubated further at 4°C. Subsamples over time were assayed for Factor VII activity in the clotting assay. Activation of increasing physiologic amounts of purified native Factor IX resulted in increasing activation of partially purified Factor VII (Fig. 5) . The data plotted in the bottom line and the top line of Fig. 5 also show that Factor XIa by itself had no measureable effect upon Factor VII activity. These experiments were also performed at an incubation temperature of 37°C with similar results.
Additional direct evidence for the activation of Factor VII by Factor IXa was obtained in experiments in which preparations of purified Factor IXa that had been stored frozen were incubated with partially purified Factor VII in the presence of calcium ions. Again, increasing concentrations of Factor IXa yielded increasing increments of Factor VII activity. For example, when partially purified Factor VII at a final concentration of 0.5-0.6 U/ml was incubated at 40C with two concentrations of Factor IXa and 5 mM CaCl2, the following increases in Factor VII clotting activity were found after 4 h: for the mixture containing a final Factor IXa concentration of 0.22 U/ml in the coupled amido-
FIGURE 5 Evidence that Factor IXa, freshly generated from purified Factor IX by purified Factor XIa and calcium ions, activates partially purified Factor VII. Purified Factor IX (25 gl) at the final concentrations shown in the figure, was incubated for 20 min at 37°C with CaCl2 (3 ,l) at a final concentration of 5.3 mM and Factor XIa (1 ,ul) at a final concentration of 1.3 U/ml. Then, Factor VII (10 ,ul) at a final concentration of 0.6-1.0 U/ml was added and the mixtures were incubated at 4°C. Subsamples were removed at the times shown for measurement of Factor VII clotting activity. (The Factor IXa concentrations, after adding the Factor VII and assuming full conversion of Factor IX to Factor IXa equaled 0.75 of the concentrations of Factor IX given in the figure).
The bottom line labeled XIa (-) represents a control experiment in which TBS-BSA replaced Factor IX. Another control experiment is shown (A), in which an anti-Factor XI antiserum at a final dilution of 1:30 was added after the first incubation and allowed to react for 10 min at 37°C before the subsequent addition of the Factor VII. lytic assay and 1.0 U/ml in the electroimmunoassay, a 2.3-fold increase in Factor VII activity; for the mixture containing a final Factor IXa concentration of 0.40 U/ml in the coupled amidolytic assay and 1.8 U/ml in the electroimmunoassay, a fourfold increase in Factor VII activity. Similar experiments were repeated in the presence of increasing concentrations of an antiserum to Factor IX. Mixtures of purified Factor IXa (final concentration 1.7 U/ml in the coupled amidolytic assay, 4.3 U/ml by electroimmunoassay), and partially purified Factor VII (final concentration 1.6-2.3 U/ml) were incubated at 37°C for 3 h with different concentrations of anti-Factor IX antiserum. The antiserum at a final dilution of 1:60 in the reaction mixture abolished the three-to fourfold rise in Factor VII activity found in incubation mixtures with more diluted antiserum or without antiserum.
Finally, because bovine Factor Xa and thrombin have been shown to activate bovine Factor VII (26), the possible influence of trace contamination of incubation mixtures with these factors was studied. A specific antiserum against Factor X at a final dilution sufficient to neutralize 10 U/ml of Factor X or a specific antiserum against prothrombin at a final dilution sufficient to neutralize 1.5 A different pattern of activation was found when clotting factor-deficient plasmas were clotted, and the incubated sera were tested for Factor VII activity (Table II) . Factor VII was activated in Factor VIIIdeficient plasma and in Factor X-deficient plasma, but not in Factor IX-deficient plasma. This suggests to us that Factor IXa was the principal activator of Factor VII under these experimental conditions. The activation of Factor VII found after clotting of Factor Xdeficient plasma confirms earlier observations of Hougie (27) and of Johnston and Hjort (2) .
The experiments in which purified P3XIIa was incubated with partially purified Factor VII (Fig. 2) (30) could demonstrate that purified kallikrein directly activated purified Factor VII. In our experiments, purified kallikrein also failed to activate partially purified Factor VII. However, when Factor IX was added to reaction mixtures, Factor VII activity increased impressively (Fig. 4) . Furthermore, Factor VII activity increased when kallikrein was added either to Factor XII-deficient plasma or to Factor IX-deficient plasma. Our (2) that Factor VII was activated after clotting of blood from patients with extreme thrombocytopenia. It should also be pointed out that in some of our experiments with antisera, Factor VII was activated by Factor IXa in the absence of added calcium ions.
Experiments in which monospecific antibodies to clotting factors were added to incubation mixtures provided further evidence that Factor IXa directly activates Factor VII. Adding antibodies to prothrombin (a major contaminant of our partially purified Factor VII) or antibodies to Factor X to incubation mixtures of purified Factor IXa and partially purified Factor VII did not impede the activation of Factor VII, whereas adding antibodies to Factor IX abolished the activation of Factor VII. This would seem to eliminate the possibility that contaminating thrombin or Factor Xa, rather than Factor IXa, could have been responsible for the activation of Factor VII in such incubation mixtures. An antiserum to Factor IX was also used to rule out the possibility that Factor IXa might activate Factor VII in plasma not only by a direct mechanism but also by an indirect mechanism. Thus, Factor VII was not activated when Factor IXa was incubated with Factor VII-deficient plasma, to allow for generation of any possible intermediate, and then the Factor IXa was neutralized by antibodies to Factor IX before the addition of Factor VII to the mixture.
It is also important to point out that Factor IXa activated Factor VII at 37°C as well as at 4°C. Activation at 37°C was demonstrated both in the experiments with recalcified plasma and also in incubation mixtures of purified Factor IX and partially purified Factor VII. Thus, the potential importance of this pathway of Factor VII activation is not necessarily limited to the phenomenon of cold-activation of plasma Factor VII (33) .
A schematic diagram that summarizes our conclusions from the data is presented in Fig. 6 . It shows two pathways for the activation of Factor VII, one through Factor XIIa and the other through Factor IXa. Kallikrein does not activate Factor VII directly and is depicted as activating Factor VII indirectly through both pathways. Apparently, when plasma is exposed to maximum surface contact through incubation with kaolin, sufficient Factor XIIa is generated to cause extensive activation of Factor VII independent of the Factor IXa pathway. When plasma is clotted and the serum incubated under the conditions used here, Factor IXa appears to function as a principal activator of Factor VII. 
